Literature DB >> 17008949

Gefitinib concentrations in human glioblastoma tissue.

Silvia Hofer1, Karl Frei.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17008949     DOI： 10.1007/s11060-006-9257-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  2 in total

1.  Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry.

Authors:  Ming Zhao; Carol Hartke; Antonio Jimeno; Jing Li; Ping He; Yelena Zabelina; Manuel Hidalgo; Sharyn D Baker
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-05-05       Impact factor: 3.205

2.  Gefitinib accumulation in glioblastoma tissue.

Authors:  Silvia Hofer; Karl Frei; Hans Peter Rutz
Journal:  Cancer Biol Ther       Date:  2006-05-05       Impact factor: 4.742
  2 in total
  18 in total

Review 1.  Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.

Authors:  Megan O Jacus; Vinay M Daryani; K Elaine Harstead; Yogesh T Patel; Stacy L Throm; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

Review 2.  Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.

Authors:  Sagar Agarwal; Ramola Sane; Rajneet Oberoi; John R Ohlfest; William F Elmquist
Journal:  Expert Rev Mol Med       Date:  2011-05-13       Impact factor: 5.600

3.  MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis.

Authors:  Yan Cheng; Yi Zhang; Li Zhang; Xingcong Ren; Kathryn J Huber-Keener; Xiaoyuan Liu; Lei Zhou; Jason Liao; Heike Keihack; Li Yan; Eric Rubin; Jin-Ming Yang
Journal:  Mol Cancer Ther       Date:  2011-11-04       Impact factor: 6.261

4.  Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.

Authors:  Sagar Agarwal; Ramola Sane; Jose L Gallardo; John R Ohlfest; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2010-04-26       Impact factor: 4.030

Review 5.  Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up.

Authors:  Sagar Agarwal; Anika M S Hartz; William F Elmquist; Björn Bauer
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

6.  Intratumoral modeling of gefitinib pharmacokinetics and pharmacodynamics in an orthotopic mouse model of glioblastoma.

Authors:  Jyoti Sharma; Hua Lv; James M Gallo
Journal:  Cancer Res       Date:  2013-06-24       Impact factor: 12.701

7.  Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.

Authors:  Sagar Agarwal; Rajendar K Mittapalli; David M Zellmer; Jose L Gallardo; Randy Donelson; Charlie Seiler; Stacy A Decker; Karen S Santacruz; Jenny L Pokorny; Jann N Sarkaria; William F Elmquist; John R Ohlfest
Journal:  Mol Cancer Ther       Date:  2012-08-13       Impact factor: 6.261

8.  Gefitinib selectively inhibits tumor cell migration in EGFR-amplified human glioblastoma.

Authors:  Jonathon J Parker; Kalen R Dionne; Rada Massarwa; Marci Klaassen; Nicholas K Foreman; Lee Niswander; Peter Canoll; B K Kleinschmidt-Demasters; Allen Waziri
Journal:  Neuro Oncol       Date:  2013-06-07       Impact factor: 12.300

9.  Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma.

Authors:  Sagar Agarwal; Pooja Manchanda; Michael A Vogelbaum; John R Ohlfest; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2012-09-26       Impact factor: 3.922

10.  A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas.

Authors:  J Russell Geyer; Clinton F Stewart; Mehmet Kocak; Alberto Broniscer; Peter Phillips; James G Douglas; Susan M Blaney; Roger J Packer; Sri Gururangan; Anu Banerjee; Mark W Kieran; Larry E Kun; Richard J Gilbertson; James M Boyett
Journal:  Eur J Cancer       Date:  2010-08-12       Impact factor: 9.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.